Particle Containing A Transition, Actinide, Or Lanthanide Metal (e.g., Hollow Or Solid Particle, Granule, Etc.) Patents (Class 424/9.32)
  • Patent number: 8617522
    Abstract: Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: December 31, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Parvesh Sharma, Brij M. Moudgil, Glenn A. Walter, Stephen R. Grobmyer, Swadeshmukul Santra, Huabei Jiang, Scott Chang Brown, Edward W. Scott, Qizhi Zhang, Niclas Bengtsson
  • Publication number: 20130330279
    Abstract: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target cell types apoptosis and correspond to Y predefined target parameters associated with Z predefined target cell types in connection with treatment of at least one of the following breast cancer, glioblastoma, head and neck cancer, pancreatic cancer, lung cancer, cancer of the nervous system, gastrointestinal cancer, prostate cancer, ovarian cancer, kidney cancer, retina, cancer, skin cancer, liver cancer, genital.
    Type: Application
    Filed: December 22, 2012
    Publication date: December 12, 2013
    Applicant: NNANOAXIS, LLC
    Inventors: Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Kamisetti
  • Publication number: 20130323182
    Abstract: The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (MRI) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials, carboxymethyl dextran (CM-dextran) is the most efficient in terms of stabilizing the annealed iron oxide nanoparticles and exhibiting contrast effects.
    Type: Application
    Filed: February 6, 2012
    Publication date: December 5, 2013
    Applicant: HANWHA CHEMICAL CORPORATION
    Inventors: Taeghwan Hyeon, Yuanzhe Piao, Yong Il Park
  • Publication number: 20130315838
    Abstract: Biomaterials suitable for use as drug eluting, Magnetic Resonance Imaging (“MRI”) detectable implants for vascular occlusion are provided, as are methods of producing such biomaterials. Further, methods of treating an individual suffering from a solid tumor are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Inventors: Philippe Reb, Celine Chaix, Meriadeg Thomas
  • Publication number: 20130315839
    Abstract: Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic FeO nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic FeO nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic FeO nanoparticles in water to oxidize FeO; and exposing the oxidized hydrophilic FeO nanoparticles to an acidic buffer to dissolve and remove interior unoxidized FeO portions, and thereby to form Fe3O4 nanoparticles having an interior space.
    Type: Application
    Filed: July 31, 2013
    Publication date: November 28, 2013
    Applicant: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Chulhyun LEE, Sung Lan JEON, Min Kyung CHAE, Jee-Hyun CHO, Eun Ju JANG
  • Publication number: 20130309176
    Abstract: The present invention relates to an oil-in-water nanoemulsion composition for MRI, comprising: an aqueous phase, representing 70% to 90% by weight of the composition, advantageously 75% to 85% and more advantageously from 78% to 82% a lipid phase comprising an oil, representing 9.5% to 29.5% by weight of the composition, advantageously 14% to 25% and more advantageously 17% to 21%, a surfactant at the interface between the aqueous and lipid phases, the surfactant comprising at least one amphiphilic paramagnetic metal chelate and optionally an amphiphilic lipid; the total content of surfactant by weight relative to the oil being between 4% and 10% and advantageously between 5% and 8%; the total content of surfactant by weight relative to the composition being between 0.35% and 2.95% and advantageously between 0.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 21, 2013
    Applicants: UNIVERSITE DE BORDEAUX 1, GUERBET
    Inventors: Marc Port, Caroline Robic, Fernando Leal Calderon, Samy Chadel
  • Patent number: 8586095
    Abstract: A thermosensitive nanostructure for hyperthermia treatment. Magnetic nanoparticles are encapsulated in a thermosensitive polymer nanostructure having a lower critical solution temperature (LCST) of about 40-45° C. The thermosensitive polymer nanostructure may carry a drug. When the magnetic nanoparticles are heated to 40-45° C. by application of an alternating magnetic field in hyperthermia treatment, the thermosensitive polymer nanostructure collapses to release the drug, thus providing concurrent drug treatment.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: November 19, 2013
    Assignee: Industrial Technology Research Institute
    Inventors: Wen Hsiang Chang, Chao-Hung Kao, Chin-I Lin, Shian-Jy Wang
  • Publication number: 20130302256
    Abstract: This invention discloses a synthetic procedure for preparing nanoparticulate materials of various metal cyanide compounds containing manganese(II) ions in the crystal lattice with the surfaces coated by a hydrophilic compound, and their use as MRI contrast agents with high sensitivity, long blood circulation half lives and low toxicity at low-field and high field MR scanners.
    Type: Application
    Filed: August 29, 2011
    Publication date: November 14, 2013
    Applicant: KENT STATE UNIVERSITY
    Inventors: Songping D. Huang, Anatoly K. Khitrin, Vindya S. Perera, Murthi S. Kandanapitiye
  • Patent number: 8580230
    Abstract: A material useful as a MRI contrast agent used for medical imaging, drug delivery platform or other functions are provided as a class of non-gadolinium and non-iron oxide based materials that comprise Prussian blue materials or analogue materials. The materials may be used as T1-weighted and/or T2-weighted MRI contrast agents for imaging, including cellular imaging, in clinical diagnosis and biomedical research applications. The agent is a compound created from Prussian blue materials that is non-toxic, and can be internalized by cells through endocytosis. The Prussian blue materials may also be used for drug delivery applications. The Prussian blue materials may be administered orally to a subject in either medical imaging or drug delivery applications or dual modality MRI-Fluorescence imaging agent.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: November 12, 2013
    Assignee: Kent State University
    Inventors: Songping D. Huang, Soumitra Basu, Anatoly K. Khitrin, Mohammadreza Shokouhimehr, Eric Scott Soehnlen
  • Publication number: 20130295020
    Abstract: A radiopaque particulate material one or more of SiO2, TiO2, La2O3, Na2O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.
    Type: Application
    Filed: January 27, 2012
    Publication date: November 7, 2013
    Applicant: DALHOUSIE UNIVERSITY
    Inventors: Robert J. Abraham, Sharon Kehoe, Daniel Boyd
  • Patent number: 8574549
    Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: November 5, 2013
    Assignee: General Electric Company
    Inventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michacl Ernest Marino
  • Publication number: 20130287703
    Abstract: The present invention relates to a nanophosphor and a synthesis method thereof, and provides a nanophosphor comprising a first compound of Formula 1, wherein the first compound is fluoride-based one which is co-doped with Ce3+ and Tb3+. NaGd1?p?q?rMrF4:Ce3+p,Tb3+q ??(1) In the Formula 1, descriptions on the p, q, r and M are overlapped with what was described in the detailed description of the present invention, so their concrete description are omitted. The nanophosphor has good light emission intensity and magnetic property as well as up-conversion and/or down-conversion property able to emit visible light after excitation by infrared and/or ultraviolet rays, so can be applied to a contrast agent and a counterfeit prevention code.
    Type: Application
    Filed: April 24, 2013
    Publication date: October 31, 2013
    Applicant: Korea Institute Of Science And Technology
    Inventors: Ho Seong JANG, Kyoungja WOO, Kipil LIM
  • Patent number: 8568690
    Abstract: The present invention provides an MRI contrast agent, comprising: MRI contrast agent particles, and oligonucleotides, attached to the particles.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: October 29, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Yi Lu, Mehmet Veysel Yigit, Debapriya Mazumdar
  • Publication number: 20130280165
    Abstract: The invention is directed to a method for preparing a microsphere comprising a lanthanide metal phosphate complex, a microsphere, a powder comprising a number of the microspheres, a suspension comprising the microsphere or the powder, the use of the microsphere, a method for detecting a tumour, and a therapeutic composition comprising the microsphere, the powder, or the suspension.
    Type: Application
    Filed: November 4, 2011
    Publication date: October 24, 2013
    Applicant: UMC Utrecht Holding B.V.
    Inventors: Wouter Bult, Johannas Franciscus Wilhelmus Nijsen, Alfred Drik Van het Schip
  • Patent number: 8562953
    Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is CH2CH2Ol, and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: October 22, 2013
    Assignee: Industrial Technology Research Institute
    Inventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
  • Publication number: 20130251641
    Abstract: The present disclosure provides compositions comprising 2-deoxyglucose-functionalized magnetic nanoparticles. The compositions are useful in various applications, which are also provided.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 26, 2013
    Applicant: The Regents of the Universtiy of California
    Inventors: MASSOUD AKHTARI, JEROME ENGEL
  • Patent number: 8540965
    Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: September 24, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jón Njardarson, Mark Reid Philips
  • Publication number: 20130243699
    Abstract: The design of biodegradable magnetic nanoparticles for use in in-vivo biomedical applications. The particles can include Fe in combination with one or more of Mg, Zn, Si, C, N, and P atoms or other particles. The nanoparticles can be degraded in-vivo after usage. The nanoparticles can cease heating upon reaching a predetermined temperature or other value.
    Type: Application
    Filed: December 7, 2012
    Publication date: September 19, 2013
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Jian-Ping Wang, Ying Jing, Shihai He
  • Publication number: 20130225979
    Abstract: The present invention relates to a method for colon screening by using Magnetic Particle Imaging comprising the steps of: (a) generating an imaging magnetic field with a spatial distribution of the magnetic field strength such that the area of examination in the colon consists of a first sub-area of the colon with lower magnetic field strength, where the magnetization of a magnetic particle which was pre-delivered to the colon is not saturated, and a second sub-area of the colon with a higher magnetic field strength, where the magnetization of said magnetic particle is saturated; (b) changing the spatial location of both sub-areas in the area of examination so that the magnetization of said particles changes locally; (c) acquiring signals that depend on the magnetization in the area of examination influenced by this change; and (d) evaluating said signals to obtain information about the spatial distribution of the signals in the area of examination.
    Type: Application
    Filed: November 7, 2011
    Publication date: August 29, 2013
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Jörn Borgert, Ingo Schmale, Jürgen Erwin Rahmer, Bernhard Gleich, Michael Harald Kuhn
  • Publication number: 20130224122
    Abstract: Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria. Magnetospirillum magneticum AMB-1 produces positive MRI contrast when generating ultrasmall magnetite particles (10-40 nm diameter). Positive MRI contrast permits clearer distinction from image voids compared to negative contrast. T1-weighted MRI showed that such bacteria increased positive contrast 2.2-fold (p<0.02) in vitro and 2.0-fold (p<0.02) following intratumoral injection in mouse tumor xenografts. Upon intravenous delivery, Magnetospirillum magneticum AMB-1 targeted tumors and generated increased positive MRI contrast in them (1.4-fold; p<0.01). AMB-1 tumor targeting was shown by viable counts, microPET imaging of radio-labeled AMB-1, and Prussian blue staining of tumor sections. Thus, magnetotactic bacteria provide a tool for improving cancer diagnosis and monitoring treatment response by MRI.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 29, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventor: The Board of Trustees of the Leland Stanford Junior University
  • Patent number: 8501159
    Abstract: There are described nanoparticles of magnetic metal oxides employable in constructs consisting in polymer particles possibly also incorporating pharmacologically active substances.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: August 6, 2013
    Assignee: Colorobbia Italia S.p.A.
    Inventors: Giovanni Baldi, Daniele Bonacchi, Franco Innocenti, Giada Lorenzi, Marco Bitossi, Paolo Ferruti, Elisabetta Ranucci, Alfredo Ricci, Mauro Comes Franchini
  • Publication number: 20130195767
    Abstract: A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.
    Type: Application
    Filed: May 26, 2011
    Publication date: August 1, 2013
    Inventors: Ralph Weissleder, Hakho Lee, Tae-Jong Yoon
  • Publication number: 20130177503
    Abstract: Methods are provided for the generation of nanostructures suitable for use in magnetic resonance imaging where the nanostructures have at least one dimension of about 2 nm or less. In particular, the methods comprise the selective use of incubation temperatures that result in the controlled removal of ligands from metallic cores to which they are attached, allowing the metallic cores or the precursor moieties to unite to form nanostructures of defined and predictable shapes, but having at least one dimension significantly less that at least one other dimension. Accordingly, the nanostructures of the disclosure may be ultrathin sheets, rods, whiskers and the like, or even structures that are thin and porous resembling rice grains. The temperatures useful in the methods of the disclosure are less than 300° C. and allow for progressive elevation of the incubation temperature.
    Type: Application
    Filed: September 26, 2011
    Publication date: July 11, 2013
    Inventor: Yuping Y. Bao
  • Patent number: 8475768
    Abstract: The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: July 2, 2013
    Assignee: GE Healthcare AS
    Inventors: Oskar Axelsson, Harry John Wadsworth, Ian Martin Newington, Dennis O'Shea
  • Publication number: 20130164222
    Abstract: Provided are a preparation method of iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles, iron oxide-based nanoparticles prepared by the same, and a T1 contrast agent including the same. More particularly, the disclosure describes a method for preparation of iron oxide nanoparticles having a extremely small and uniform size of 4 nm or less based on thermal decomposition of iron oleate complex, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles prepared by the same, and a T1 contrast agent including iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles.
    Type: Application
    Filed: August 5, 2011
    Publication date: June 27, 2013
    Applicant: Hanwha Chemical Corporation
    Inventors: Taeg Hwan Hyeon, Byung Hyo Kim, No Hyun Lee, Eung Gyu Kim, Bong Sik Jeon, Eun Byul Kwon, Ju Young Park, Wan Jae Myeong
  • Patent number: 8470892
    Abstract: A method for inducing neovascularization in which a pharmaceutically effective amount of polyethylene glycol (PEG) is injected into the tissue of the subject for purposes of accelerating wound healing and mimicking age related macular degeneration, cancer, tumors, and atherosclerosis for further research purposes.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: June 25, 2013
    Inventors: Puran S. Bora, Nalini S. Bora
  • Publication number: 20130129633
    Abstract: Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging.
    Type: Application
    Filed: December 28, 2012
    Publication date: May 23, 2013
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
  • Publication number: 20130129632
    Abstract: The disclosure provides quantum dot materials, compositions and methods useful in the treatment of various disorders. In particular, the disclosure provides cadmium-free and lead-free quantum dots.
    Type: Application
    Filed: October 3, 2012
    Publication date: May 23, 2013
    Inventors: Kam W. Leong, Chai-Hoon Quek
  • Publication number: 20130115172
    Abstract: The present invention relates to a nanophosphor and method for synthesizing the same, and provides a nanophosphor containing fluoride-based nanoparticles co-doped with Yb3+ and Er3+ expressed by the following Chemical Formula 1, NaY1?w?z?x?yGdwLzF4:Yb3+x,Er3+y??(1) wherein, the description of the values x, y, w, z, and L is the same as defined above. The nanophosphor may exhibit an excellent luminous intensity despite having a small particle size, and be excited by infrared rays to emit visible light, and have magnetic properties and thus can be used as a contrast agent, a counterfeit prevention code, and the like.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 9, 2013
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventor: Korea Institute of Science and Technology
  • Publication number: 20130108552
    Abstract: The subject invention provides novel fluorescent core-shell nanoparticles comprising an encapsulated fluorescent core comprising an ionically bound fluorescent dye and a metal oxide shell. In one exemplary embodiment of the invention a core containing indocyanine green (ICG) with a silica shell that displays excellent photostability for generation of a near infrared fluorescence signal. The fluorescent core-shell nanoparticle can be further modified to act as an MRI, x-ray, or PAT contrast agent. The ICG nanoparticles can also be used as photodynamic therapeutic agent. Other embodiments of the invention directed to methods of making the novel core-shell nanoparticles and to the use of the core-shell nanoparticles for in vitro or in vivo imaging.
    Type: Application
    Filed: February 24, 2011
    Publication date: May 2, 2013
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.
    Inventors: Parvesh Sharma, Scott Chang Brown, Niclas Bengtsson, Glenn A. Walter, Nobutaka Iwakuma, Edward W. Scott, Stephen R. Grobmyer, Swadeshmukul Santra, Brij M. Moudgil
  • Patent number: 8420127
    Abstract: An injectable bone mineral substitute material composition with the capability of being hardened in a body fluid in vivo, which comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture mixed with an aqueous liquid, and at least one accelerator, the at least one calcium sulfate component being particulate hardened calcium sulfate, which has a specified particle size that is in order to confer injectability to the composition. The invention also concerns the bone mineral substitute material produced from the composition as well as methods and uses thereof.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: April 16, 2013
    Assignee: Bone Support AB
    Inventors: Lars Lidgren, Malin Nilsson
  • Publication number: 20130052140
    Abstract: This invention provides a Fe3O4/TiO2 composite nano-particle, its preparation and application in the magnetic resonance imaging (MRI) contrast agent, wherein the preparation of Fe3O4/TiO2 composite nano-particles has the followings steps: trivalent iron compounds and bivalent iron compounds are dissolved into a reducing acid water solution, and then added with tetravalent titanium salt solution to obtain the Fe3O4/TiO2 composite nano-particle sol. The Fe3O4/TiO2 composite nano-particles prepared by the method in the invention have the properties of superparamagnetism and photocatalytic activity and can be applied to MRI contrast agents.
    Type: Application
    Filed: October 15, 2010
    Publication date: February 28, 2013
    Inventors: Leyong Zeng, Aiguo Wu, Ping Cui
  • Patent number: 8383085
    Abstract: A method of making iron-containing nanoparticles (e.g., magnetite nanoparticles) that includes contacting an iron-containing precursor with a reducing agent at a temperature less than 200° C. and allowing the mixture to react to form magnetite nanoparticles.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: February 26, 2013
    Assignee: University of Manitoba
    Inventors: Torsten Hegmann, Vinith Yathindranath, David F. Moore, Johan van Lierop
  • Patent number: 8367040
    Abstract: Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 5, 2013
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Jenny Jie Yang, Zhi-Ren Liu
  • Publication number: 20130023714
    Abstract: In one embodiment the present invention discloses a nanocluster or a nanorose composition comprising two or more closely spaced nanoparticles each comprising one or more metals, metal oxides, inorganic substances, or a combination thereof and one or more stabilizers. The stabilizers are in contact with the two or more closely spaced nanoparticles to form a nanocluster composition in which the inorganic weight percentage is greater than 50% and the average size is below 300 nm, and the nanocluster composition has magnetic properties, optical properties or a combination of both.
    Type: Application
    Filed: October 26, 2009
    Publication date: January 24, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS
    Inventors: Keith P. Johnston, Li L. Ma, Marc D. Feldman, Thomas E. Milner, Konstantin V. Sokolov, Jasmine Rowe, Justina Tam, Stanislav Emelianov, Kort Travis, Avinash K. Murthy
  • Publication number: 20130017155
    Abstract: The invention relates to a new tungsten-iron-Ferritin nanoparticle and uses thereof in imaging.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 17, 2013
    Inventors: Kevin Bennett, Simon Lubek, Maria Veronia Clavijo-Jordan
  • Patent number: 8349293
    Abstract: The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 8, 2013
    Assignee: Guerbet
    Inventor: Claire Corot
  • Patent number: 8349294
    Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: January 8, 2013
    Assignee: Novartis AG
    Inventors: Luis A Dellamary, Jean Riess, Ernest G Schutt, Jeffry G Weers, Thomas E Tarara
  • Patent number: 8323618
    Abstract: The present invention provides biomimetic contrast agents, dual functional contrast agents effective for therapeutic gene delivery and magnetic nanoparticles which comprise functionalized iron oxide nanoparticle cores, one of an inert gold layer, a layer of inert metal seeds or a silica layer and, optionally, one or both of an outer gold-silver nanoshell or a targeting ligand attached to the inert gold layer or the gold-silver nanoshell. Also provided are methods of in vivo magnetic resonance imaging, of treating primary or metastatic cancers or of ablating atherosclerotic plaque using the contrast agents and magnetic particles. In addition, kits comprising the biomimetic contrast agents, dual contrast agents and magnetic nanoparticles.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: December 4, 2012
    Assignee: University of Houston System
    Inventor: Malavosklish Bikram
  • Patent number: 8323621
    Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: December 4, 2012
    Assignees: Vanderbilt University, Texas Tech University System
    Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
  • Patent number: 8303937
    Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: November 6, 2012
    Assignee: Industrial Technology Research Institute
    Inventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
  • Publication number: 20120276005
    Abstract: Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1—Y—X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X1 and X2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.
    Type: Application
    Filed: April 3, 2012
    Publication date: November 1, 2012
    Inventors: David Yang, Dongfang Yu, Mithu Chanda, Ali Azhdarinia, Changsok Oh, E. Edmund Kim
  • Publication number: 20120259154
    Abstract: The invention is a nano-entity conjugate for use in an in vivo immunomagnetic hyperthermia system for the detection and treatment of any cell or virus having a target surface receptor which encompasses a technology platform that can be used for both real-time monitoring of any cell or virus having a target surface receptor and as a delivery platform for certain types of treatment that are conducive for in vivo applications. The system allows of cell or virus enumeration; cell or virus capture; and cell or virus removal from the patient's circulatory system in-vivo using immunomagnetic hyperthermia. The application of immunomagnetic hyperthermia may actually diminish and eventually stop the progression of cancer and other blood borne or blood affected diseases.
    Type: Application
    Filed: April 5, 2011
    Publication date: October 11, 2012
    Applicant: IVDiagnostics, Inc.
    Inventors: Bin Hong, Brian Markey
  • Publication number: 20120258051
    Abstract: A composition comprising a core comprising an iron oxide, a first shell comprising at least one plasmon active metal at least partially surrounding the core, a second shell comprising a dielectric material at least partially surrounding the first shell, and a third shell comprising at least one plasmon active metal at least partially surrounding the second shell.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 11, 2012
    Inventors: Charleson S. Bell, Shann Yu
  • Publication number: 20120251443
    Abstract: The present disclosure provides compositions and methods based on implantable contrast agents that are useful for imaging tissue and organs.
    Type: Application
    Filed: October 1, 2010
    Publication date: October 4, 2012
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: C. Keith Ozaki, Jeffrey M. Karp, Frank Rybicki, Dimitrios Mitsouras, Praveen Kumar Vemula
  • Publication number: 20120219508
    Abstract: In one aspect, there is provided a compound comprising an acetylated carboxymethylcellulose (CMC-Ac) covalently linked to: at least one poly(ethylene glycol) (PEG), and at least one hydrophobic drug. In another aspect, a self-assembling nanoparticle composition comprising such compounds is provided.
    Type: Application
    Filed: February 1, 2012
    Publication date: August 30, 2012
    Inventors: SHYH-DAR LI, Mark John Ernsting, Wei-Lun Tang
  • Publication number: 20120201759
    Abstract: Hierarchical nanostructures and methods of fabrication. The structures include particles having a metal oxide outer shell with metal oxide wires extending from the outer shell. A multiscale structure according to the invention has particles above and below a critical size wherein the particles above the critical size have wires extending from the surface. These structures may be fabricated from a mixture prepared of relatively smaller metal particles having a size threshold below a threshold for nanowire formation and of relatively larger metal particles having a size above the threshold for nanowire formation. The mixture is oxidized at a selected temperature and for a selected time whereby the relatively smaller particles sinter and nanowires grow on the relatively larger particles thereby creating tunable hierarchical structures with metal-to-metal contact between the particles.
    Type: Application
    Filed: February 1, 2012
    Publication date: August 9, 2012
    Applicant: Massachusetts Institute of Technology
    Inventors: Christopher Jameson Love, J. David Smith, Kripa K. Varanasi
  • Publication number: 20120195835
    Abstract: A bio-imaging nanoparticle is composed of a core nanoparticle, a bonding layer having organic ligands, surfactants and polyoxyalkylene derivatives of fatty acid ester, and veiling the core nanoparticle, and functional molecules, wherein the organic ligands are bound to a surface of the core nanoparticle, the surfactants are bound to a portion of the surface of the core nanoparticle to which the organic ligands are not bound, the polyoxyalkylene derivatives of the fatty acid ester are introduced in an empty space between the organic ligands and the surfactants of the bonding layer, and the functional molecule is bound to a second terminal end opposite to a first terminal end of both terminal ends of the organic ligand, the first terminal end of the organic ligand being bound to a shell of the core nanoparticle.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kyoungja WOO, Myung-Ik YOO
  • Publication number: 20120197115
    Abstract: The invention relates to the discrimination of spectroscopically different tracer materials by magnetic particle imaging (MPI), based on the differences of the MPI spectral responses of said tracer materials.
    Type: Application
    Filed: October 11, 2010
    Publication date: August 2, 2012
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Peter Leonardus Elisabeth Maria Pasmans, Denis Markov
  • Publication number: 20120190975
    Abstract: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a copper (Cu)-based nanoparticle and a method for making the same. The Cu-based nanoparticles can further be incorporated with additional therapeutic or diagnostic compounds and used for the diagnosis and treatment of tumors.
    Type: Application
    Filed: June 22, 2011
    Publication date: July 26, 2012
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Wei Chen, Yuebin Li